A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy.
about
Structure and specificity of an antibody targeting a proteolytically cleaved IgG hingeEffects of antibody disulfide bond reduction on purification process performance and final drug substance stabilityEngagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activationTwo dimensions in targeting HER2.Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cellsHER2-family signalling mechanisms, clinical implications and targeting in breast cancer.HER2-positive breast cancer is lost in translation: time for patient-centered research.Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages.A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.Assessment of disulfide and hinge modifications in monoclonal antibodiesEngineered protease-resistant antibodies with selectable cell-killing functions.HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic responseAntibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CATumor evasion of humoral immunity mediated by proteolytic impairment of antibody triggered immune effector function.Metal ion interactions with mAbs: Part 1.Site-specific proteolytic degradation of IgG monoclonal antibodies expressed in tobacco plants.Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-Glycoprotein B Bispecific Antibody.Microheterogeneity of Recombinant Antibodies: Analytics and Functional Impact.9th annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland.Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo.
P2860
Q27689552-BB4A2A1A-FDE0-4D72-80BC-EE3EECC47222Q33628551-86906666-DE4C-459E-B0AE-C98AF694D584Q33739796-C3852999-45A3-4984-8D91-DF67A07B46CAQ35895143-174086BD-D71A-4020-BA25-EB60427AF50BQ37589825-0EA6A762-674B-4F90-8338-9FD5745D2055Q38301236-38E20FD8-8421-404E-A2F7-5DDFD6B44A47Q38648765-6D0C9458-FD17-43D2-A94D-FBCB974B78BDQ38852051-311BDB65-8202-4A92-88E6-00A9537DB882Q38880179-14D76BA1-A317-4F79-9353-5AC85B30CF9AQ38896842-84A6EB3B-67DD-4123-9A35-B0698EAB1339Q38927756-BBEF8D8B-98E6-4723-8399-03C59F0D1E70Q39041113-6E08B155-D922-4100-B147-35E863C8B43CQ39103601-A48B38AD-AC5F-420F-86E0-69782201921AQ41551956-A73B9E01-88A2-4F56-9B94-0091C5DB2583Q42557137-76DD3FB4-696A-425E-AF85-46CF07BE78F9Q42577749-F54D852B-1D5B-4EA2-ADA0-F3211D936AFDQ43199899-E0AEAB1D-97BC-422E-88FC-F19790F2A3F5Q44272919-0ED85DB2-392A-45DB-8835-EC7B641A305BQ47610511-17061A0B-44C3-487A-8B72-4C100186F215Q50237001-F9E61F1F-5526-419D-92BC-17D0ED9699A9Q51238255-781D6981-3E43-4D26-B757-6D52C48BC397Q55015029-C46487E2-868F-48C7-9E21-6920A56DB299
P2860
A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A single proteolytic cleavage ...... function and in vivo efficacy.
@en
type
label
A single proteolytic cleavage ...... function and in vivo efficacy.
@en
prefLabel
A single proteolytic cleavage ...... function and in vivo efficacy.
@en
P2093
P2860
P356
P1476
A single proteolytic cleavage ...... function and in vivo efficacy.
@en
P2093
Allison Oberholtzer
Anneliese Gonzalez
Ningyan Zhang
Randall J Brezski
Robert E Jordan
William P Dubinsky
William R Strohl
Xuejun Fan
P2860
P2888
P356
10.1186/BCR3240
P577
2012-08-08T00:00:00Z
P5875
P6179
1032857518